Legal & General Group PLC Xencor Inc Transaction History

Legal & General Group PLC

  • $368 Billion
  • Q4 2024

A detailed history of Legal & General Group PLC transactions in Xencor Inc stock. As of the latest transaction made, Legal & General Group PLC holds 191,514 shares of XNCR stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
191,514
Previous 171,373 11.75%
Holding current value
$2.87 Million
Previous $3.45 Million 27.68%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$19.43 - $26.84 $391,339 - $540,584
20,141 Added 11.75%
191,514 $4.4 Million
Q3 2024

Feb 28, 2025
SELL
$15.7 - $21.65 $385,874 - $532,113
-24,578 Reduced 12.83%
166,936 $3.36 Million
Q3 2024

Nov 14, 2024
SELL
$15.7 - $21.65 $269,082 - $371,059
-17,139 Reduced 9.09%
171,373 $3.45 Million
Q2 2024

Aug 14, 2024
BUY
$18.21 - $24.5 $2,349 - $3,160
129 Added 0.07%
188,512 $3.57 Million
Q1 2024

May 14, 2024
BUY
$18.65 - $26.52 $342,451 - $486,960
18,362 Added 10.8%
188,383 $4.17 Million
Q4 2023

Feb 15, 2024
BUY
$16.53 - $21.42 $38,961 - $50,486
2,357 Added 1.41%
170,021 $3.61 Million
Q3 2023

Nov 14, 2023
SELL
$20.08 - $25.39 $1.13 Million - $1.43 Million
-56,276 Reduced 25.13%
167,664 $3.38 Million
Q2 2023

Aug 14, 2023
SELL
$24.77 - $29.9 $337,144 - $406,968
-13,611 Reduced 5.73%
223,940 $5.59 Million
Q1 2023

May 15, 2023
BUY
$25.95 - $36.95 $406,558 - $578,895
15,667 Added 7.06%
237,551 $6.63 Million
Q4 2022

Feb 14, 2023
BUY
$24.79 - $30.86 $312,527 - $389,052
12,607 Added 6.02%
221,884 $5.78 Million
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $914,214 - $1.2 Million
37,133 Added 21.57%
209,277 $5.44 Million
Q2 2022

Aug 22, 2022
SELL
$19.74 - $29.01 $129,731 - $190,653
-6,572 Reduced 3.68%
172,144 $4.71 Million
Q1 2022

May 16, 2022
SELL
$26.68 - $41.63 $570,071 - $889,508
-21,367 Reduced 10.68%
178,716 $4.77 Million
Q4 2021

Feb 14, 2022
BUY
$33.67 - $43.44 $187,844 - $242,351
5,579 Added 2.87%
200,083 $8.03 Million
Q3 2021

Nov 15, 2021
BUY
$30.65 - $35.68 $1.32 Million - $1.54 Million
43,217 Added 28.57%
194,504 $6.35 Million
Q2 2021

Aug 12, 2021
SELL
$34.33 - $44.68 $1.32 Million - $1.72 Million
-38,538 Reduced 20.3%
151,287 $5.22 Million
Q1 2021

May 17, 2021
BUY
$40.81 - $53.88 $134,958 - $178,181
3,307 Added 1.77%
189,825 $8.17 Million
Q4 2020

Feb 12, 2021
BUY
$36.63 - $47.63 $17,765 - $23,100
485 Added 0.26%
186,518 $8.14 Million
Q3 2020

Nov 13, 2020
BUY
$30.09 - $43.02 $827,144 - $1.18 Million
27,489 Added 17.34%
186,033 $7.22 Million
Q2 2020

Aug 14, 2020
BUY
$27.76 - $33.42 $332,092 - $399,803
11,963 Added 8.16%
158,544 $5.14 Million
Q1 2020

May 14, 2020
SELL
$20.69 - $37.79 $83,008 - $151,613
-4,012 Reduced 2.66%
146,581 $4.38 Million
Q4 2019

Feb 13, 2020
BUY
$32.75 - $41.43 $317,609 - $401,788
9,698 Added 6.88%
150,593 $5.18 Million
Q3 2019

Nov 13, 2019
BUY
$33.73 - $46.27 $4.1 Million - $5.62 Million
121,474 Added 625.48%
140,895 $4.75 Million
Q2 2019

Aug 14, 2019
BUY
$29.6 - $40.93 $13,260 - $18,336
448 Added 2.36%
19,421 $795,000
Q1 2019

May 15, 2019
BUY
$27.85 - $38.09 $6,823 - $9,332
245 Added 1.31%
18,973 $589,000
Q4 2018

Feb 15, 2019
BUY
$32.39 - $42.05 $49,135 - $63,789
1,517 Added 8.81%
18,728 $678,000
Q3 2018

Nov 20, 2018
BUY
$35.69 - $47.65 $354,544 - $473,355
9,934 Added 136.51%
17,211 $671,000
Q2 2018

Aug 10, 2018
BUY
$28.41 - $42.41 $4,886 - $7,294
172 Added 2.42%
7,277 $269,000
Q1 2018

May 17, 2018
SELL
$21.18 - $33.78 $55,279 - $88,165
-2,610 Reduced 26.87%
7,105 $213,000
Q4 2017

Feb 13, 2018
BUY
$19.29 - $24.83 $187,402 - $241,223
9,715
9,715 $214,000

Others Institutions Holding XNCR

# of Institutions
199
Shares Held
73.7M
Call Options Held
1.7K
Put Options Held
4.2K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $894M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email